The $1,000 genome, the $100,000 analysis? by Mardis, Elaine R
Having recently attended the Personal Genomes meeting 
at Cold Spring Harbor Laboratories (I was an organizer 
this  year),  I  was  struck  by  the  number  of  talks  that 
described  the  use  of  whole-genome  sequencing  and 
analysis to reveal the genetic basis of disease in patients. 
These  patients  included  a  child  with  irritable  bowel 
disease, a child with severe combined immunodeficiency, 
two siblings affected with Miller syndrome, and several 
with cancers of different types. Although each presenter 
emphasized the rapidity with which these data can now 
be  generated  using  next-generation  sequencing  instru-
ments,  they  also  listed  the  large  number  of  people 
involved in the analysis of these datasets. The required 
expertise  to  ‘solve’  each  case  included  molecular  and 
computational  biologists,  geneticists,  pathologists  and 
physicians with exquisite knowledge of the disease and of 
treatment  modalities,  research  nurses,  genetic  coun-
selors,  and  IT  and  systems  support  specialists,  among 
others. While much of the attendant effort was focused 
on  the  absolute  importance  of  obtaining  the  correct 
diagnosis, the large number of specialists was critical for 
the  completion  of  the  data  analysis,  the  annotation  of 
variants, the interpretive ‘filtering’ necessary to deduce 
the causative or ‘actionable’ variants, the clinical verifi-
cation  of  these  variants,  and  the  communication  of 
results and their ramifications to the treating physician, 
and  ultimately  to  the  patient.  At  the  end  of  the  day, 
although the idea of clinical whole-genome sequencing 
for diagnosis is exciting and potentially life-changing for 
these  patients,  one  does  wonder  how,  in  the  clinical 
translation required for this practice to become common-
place,  such  a  ‘dream  team’  of  specialists  would  be 
assembled for each case. In other words, even if the cost 
and speed of generating sequencing data continue their 
precipitous decreases, the cost of ‘team’ analysis seems 
unlikely to immediately follow suit. However, rather than 
predicting from this reasoning that widespread diagnosis 
by sequencing is unlikely to occur widely, it is perhaps 
more fruitful to predict, in my opinion, what is probably 
required for it to occur. I therefore offer the following as 
food for thought.
One  source  of  difficulty  in  using  resequencing 
approaches for diagnosis centers on the need to improve 
the  quality  and  completeness  of  the  human  reference 
genome. In terms of quality, it is clear that the clone-
based methods used to map, assign a minimal tiling path, 
and sequence the human reference genome did not yield 
a  properly  assembled  or  contiguous  sequence  equally 
across all loci. Lack of proper assembly is often due to 
collapsing of sequence within repetitive regions, such as 
segmental duplications, wherein genes can be found once 
the correct clones are identified and sequenced. At some 
loci, the current reference contains a single nucleotide 
polymorphism  (SNP)  that  occurs  at  the  minor  allele 
frequency rather than being the major allele. In addition, 
some loci cannot be represented by a single tiling path 
and require multiple clone tiling paths to capture all of 
the  sequence  variations.  All  of  these  deficiencies  and 
others not cited provide a less-than-optimal alignment 
target  for  next-generation  sequencing  data  and  can 
confound the analytical validity of variants necessary to 
properly interpret patient-derived data. Hence, although 
it is difficult work to perform, the ongoing efforts of the 
Genome Resource Consortium [1] to improve the overall 
completeness  and  correctness  of  the  human  reference 
genome should be enhanced.
Along these lines, although projects such as the early 
SNP Consortium [2], the subsequent HapMap projects [3-
5], and more recently the 1,000 Genomes Project [6] have 
identified millions of SNPs in multiple ethnic groups, there 
is much more diversity to the human genome than single 
base  differences.  In  some  ways,  the  broader  scope  of 
‘beyond  SNP’  diversity  of  the  genome  across  human 
populations remains mysterious, including common copy 
number  polymorphisms,  large  insertions  and  deletions, 
and  inversions.  Mining  the  1,000  Genomes  data  using 
methods  to  identify  genome-wide  structural  variation 
should  augment  this  considerably  [7],  with  validation 
playing  an  important  role,  as  many  methods  are  still 
nascent. Lastly, devising clever ways to provide all such 
classes of variants as a ‘searchable space’ for sequence data 
alignment  remains  a  significant  challenge,  as  does  the 
development  of  sequence  alignment  algorithms  that 
facilitate the analysis of structurally complex loci. © 2010 BioMed Central Ltd
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© 2010 BioMed Central LtdHow well do we understand the functions encoded by 
our genome? Certainly, comprehensive functional infor-
ma  tion  about  proteins,  including  the  impact  of  muta-
tions, is complete for relatively few genes. The develop-
ment of high-throughput systems for biochemistry and 
enzymology  could  have  a  dramatic  impact  on  this 
deficiency and would add vitality to these areas of scientific 
endeavor. Efforts that annotate regulatory protein binding 
sites, sites of RNA-mediated regulatory mechanisms, and 
other motifs that contribute to transcriptional regulation 
in the human genome must continue. Improved under-
standing of these regions, and thus their annotation, will 
require the power of model-organism-based systems to 
identify  and  characterize  functional  proteins  or 
mechanisms that are shared with humans. We also must 
transfer  these  findings  into  human  cell  experimental 
systems that allow researchers to examine the impact of 
the  mutations  or  other  alterations  of  the  genome  on 
cellular pathways and the resulting disease biology. With 
functional  consequences  in  hand,  we  will  begin  to 
understand and associate the clinical validity of genomic 
variants, effectively enabling the correlation of variant(s) 
with the resultant phenotype(s).
If our efforts to improve the human reference sequence 
quality, variation, and annotation are successful, how do 
we  avoid  the  pitfall  of  having  cheap  human  genome 
resequencing but complex and expensive manual analysis 
to  make  clinical  sense  out  of  the  data?  One  approach 
would  emphasize  the  development  of  ‘clinical  grade’ 
inter  pretational  analysis  pipelines  to  perform  much  of 
the initial discovery from datasets derived from massively 
parallel sequencing [8]. Although such pipelines already 
exist  in  the  research  setting  [9],  manual  checks  and 
orthogonal validation of variants are required because of 
the ongoing development of the analytical approaches. 
Towards patient diagnoses, such validation could initially 
be performed in a clinical laboratory medicine setting, 
but ultimately we must develop sophisticated analytical 
approaches and quality filters that enable high-confidence 
variant detection solely from the primary data. All dis-
covered variants would then be interpreted in the context 
of  the  ever-improving  human  genome  annotation  and 
evaluated in the contexts of medical genetics, of demon-
strated clinical validity, and of the pharmaceutical data-
bases (when appropriate), to identify causative or thera-
peu  tically  actionable  genes.  Ultimately,  as  in  medicine 
today,  the  results  will  require  interpretation  by  a 
physician, which raises a separate but equally important 
issue:  the  significant  need  to  develop  and  implement 
training programs in genomics for medical professionals. 
Pathologists and genetic counselors will be the first in 
line  for  training  programs  focused  on  genomic  diag-
nostics,  and  improving  the  genomics  education  of 
medical  students  will  also  be  a  first  priority.  More 
challenging will be the genomics education of practicing 
physicians  and  other  medical  professionals,  many  of 
whom do not require genetics to perform their valuable 
role in health care daily, but who will be confronted in 
the near term by increasingly well informed patients who 
expect their doctors to be as well versed as they are about 
genome-guided diagnosis and treatment.
A final word on the important topic of patient access to 
genome-guided  medicine  seems  necessary  and  appro-
priate. The current high cost of whole-genome sequen-
cing  and  analysis  relative  to  most  clinical  diagnostic 
assays,  coupled  with  the  fact  that  these  costs  are  not 
currently reimbursed by insurers, might mean that only 
those with the means to pay for the test will be allowed 
access.  Perhaps  worse,  those  with  the  fattest  wallets 
might pay extra for a place higher in the queue, denying 
earlier access to patients who more desperately need the 
information. Although there are no easy answers here, 
one  plausible  solution  might  be  the  establishment  of 
funds  at  major  medical  centers,  where  genome-guided 
medicine is likely to be practiced first, that pay for the 
genomic sequencing, diagnosis and associated costs and 
thus allow equitable access to this new assay.
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